Direct delivery of immune modulators to tumour‐infiltrating lymphocytes using engineered extracellular vesicles
Journal of Extracellular Vesicles · 2025
DOI: 10.1002/jev2.70035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2025. Verfasst von Xiabing Lyu und 12 weiteren Autor:innen. Beteiligte Einrichtung: WPI Nano Life Science Institute (NanoLSI), Kanazawa University, Kanazawa, Japan. Hauptthemen laut MEDLINE: Extracellular Vesicles, Lymphocytes, Tumor-Infiltrating, Immunologic Factors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Science and Technology Corporation.
Abstract (Originalsprache)
Extracellular vesicles (EVs) are important mediators of cell–cell communication, including immune regulation. Despite the recent development of several EV‐based cancer immunotherapies, their clinical efficacy remains limited. Here, we created antigen‐presenting EVs to express peptide‐major histocompatibility complex (pMHC) class I, costimulatory molecule and IL‐2. This enabled the selective delivery of multiple immune modulators to antigen‐specific CD8 + T cells, promoting their expansion in vivo without severe adverse effects. Notably, antigen‐presenting EVs accumulated in the tumour microenvironment, increasing IFN‐γ + CD8 + T cell and decreasing exhausted CD8 + T cell numbers, suggesting that antigen‐presenting EVs transformed the ‘cold’ tumour microenvironment into a ‘hot’ one. Combination therapy with antigen‐presenting EVs and anti‐PD‐1 demonstrated enhanced anticancer immunity against established tumours. We successfully engineered humanized antigen‐presenting EVs, which selectively stimulated tumour antigen‐specific CD8 + T cells. In conclusion, engineering EVs to co‐express multiple immunomodulators represents a promising method for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- WPI Nano Life Science Institute (NanoLSI), Kanazawa University, Kanazawa, Japan.
- Department of Immunology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan.
- Laboratory for Molecular Delivery and Imaging Technology, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan.
- Department of Pharmaceutical Informatics, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
- Biological Research Laboratories, Nissan Chemical Corporation, Saitama, Japan.
ORCID-Profile: Rikinari Hanayama
Förderung
- Japan Agency for Medical Research and Development
- Japan Science and Technology Corporation
Zitieren
APA
Lyu, X., Yamano, T., Nagamori, K., Imai, S., Van Le, T., Bolidong, D., Ueda, M., Warashina, S., Mukai, H., Hayashi, S., Matoba, K., Nishino, T., & Hanayama, R. (2025). Direct delivery of immune modulators to tumour‐infiltrating lymphocytes using engineered extracellular vesicles. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.70035
Vancouver
Lyu X, Yamano T, Nagamori K, Imai S, Van Le T, Bolidong D, et al. Direct delivery of immune modulators to tumour‐infiltrating lymphocytes using engineered extracellular vesicles. Journal of Extracellular Vesicles. 2025. doi:10.1002/jev2.70035
BibTeX
@article{Lyu2025,
author = {Lyu, Xiabing and Yamano, Tomoyoshi and Nagamori, Kanto and Imai, Shota and Van Le, Toan and Bolidong, Dilireba and Ueda, Makie and Warashina, Shota and Mukai, Hidefumi and Hayashi, Seigo and Matoba, Kazutaka and Nishino, Taito and Hanayama, Rikinari},
title = {Direct delivery of immune modulators to tumour‐infiltrating lymphocytes using engineered extracellular vesicles},
journal = {Journal of Extracellular Vesicles},
year = {2025},
doi = {10.1002/jev2.70035}
}
EUVIMED